Option chain shows key data for Nuvve Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nuvve Holding.

Nuvve Holding (NASDAQ:NVVE) Stock, Option Chain

Nuvve Holding

Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.

NVVE

News

Market-Moving Exclusives

Exclusives

Tech

Nuvve Holdings showcased breakthrough AC V2G solutions, demonstrating ability to provide scalable and practical solutions for clean energy transition.

EXCLUSIVE: Nuvve Unveils Scalable V2G Solution at Exelon Event, Turning Parked EVs into Grid Powerhouses

Wall Street US stocks

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ELAB

KAVL

PRFX

ZJYL

US Stocks Edge Higher; Chicago Fed National Activity Increases In August

movers image

Pre-Market Outlook

Movers

ACIU

ADTX

CERO

CJET

GPMT

GSIW

GXAI

LGCB

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

NUKK

PGHL

SMXT

STEM

WHLR

Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Nuvve Holding Corp

Wells Fargo analyst Jared Shaw upgrades Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) from Underweight to Equal-Weight and raises the price target from $40 to $48.

Upgrades

Price Target

Analyst Ratings

Wells Fargo Upgrades Bank OZK to Equal-Weight, Raises Price Target to $48

Needham analyst Joshua Reilly reiterates AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) with a Buy and maintains $25 price target.

Reiteration

AEYE

Needham Reiterates Buy on AudioEye, Maintains $25 Price Target

Chinese smartphone maker Xiaomi&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) first EV — the SU7 — outsold American EV giant Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3 sedan in China in December.
What Happened: Xiaomi chairman Lei Jun noted the achievement in a post on the social media platform Weibo.
While 25,815 Xiaomi SU7 vehicles were sold in December, only 21,046 Model 3s were sold. The best-selling EV in the month, however, was BYD Co.&#8217;s Seagull, of which the company sold 48,754 units.
Xiaomi launched its first EV — the SU7 sedan — in late March and started delivering the vehicles in April. 
The SU7 is available in three variants, namely Standard, Pro, and Max with the lower-end variant starting at 215,900 yuan ($29,500), lower than Tesla&#8217;s cheapest offering — the Model 3 — in China.
Why It Matters: Tesla hiked the price of the Model 3 in China earlier this month by 3,600 yuan. The vehicle now starts at 235,500 yuan in the country with the higher-end Performance variant priced at 339,500 yuan.
Tesla also launched a refreshed Model Y in China this month. The refreshed vehicle starts at&nbsp;<a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition" target="_blank" rel="noreferrer noopener">263,500 yuan on Tesla&#8217;s website</a>, nearly 5.4% pricier than the older version of the vehicle which started at 249,900 yuan.&nbsp;
China is an important market for Tesla. In 2024, the company reportedly&nbsp;<a href="https://www.benzinga.com/25/01/42782683/tesla-hits-record-ev-sales-in-china-despite-global-dip" target="_blank" rel="noreferrer noopener">sold around 657,000 vehicles in China</a>, marking a growth of 8.8% year-on-year, even while its global annual deliveries fell as compared to 2023.
Tesla reported global&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a>&nbsp;vehicles in 2024, down from full-year deliveries of 1.81 million in 2023, marking the first decline in over a decade.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Shutterstock

TSLA

XIACF

Tesla Model 3 Loses To Xiaomi SU7 In China's December Sales Showdown

Management

BIRK

Birkenstock Group Appoints Ivica Krolo As Finance Chief Effective February 1, 2025

Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nsPFA&#x2122;) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting.
The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System for the treatment of AF (NCT06696170). To date, 77 patients have been treated by six investigators, including Dr. Vivek Reddy and Prof. Petr Neuzil, in cases performed at Na Holmolce Hospital in Prague and Dr. Johan Vijgen at Jessa Hospital in Hasselt. The initial cohort of the first 30 patients treated have been evaluated by remapping completed at ~3 months post ablation procedure.

Biotech

General

PLSE

Pulse Biosciences Announces Nanosecond PFA 360° Cardiac Catheter Study Results, 92.4% Success At 3 Months In Initial 30 AF Patients; IDE Study Planned For 2025

Morgan Stanley analyst Brian Harbour maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Equal-Weight and lowers the price target from $15 to $13.

PTLO

Morgan Stanley Maintains Equal-Weight on Portillos, Lowers Price Target to $13

WIIM

HSDT

Helius Medical Technologies shares are trading higher after the company announced it exceeded its initial enrollment target for its stroke pivotal study.

Needham analyst Joshua Reilly reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Buy and maintains $25 price target.

JAMF

Needham Reiterates Buy on Jamf Holding, Maintains $25 Price Target

Guidance

BLRX

BioLineRx Outlines Vision For 2025: Plans New Oncology/Rare Disease In-Licensing, 1-For-40 Reverse Stock Split To Meet Nasdaq Compliance, $29.5M Cash, Runway Through H2 2026

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Overweight and lowers the price target from $510 to $496.

Morgan Stanley Maintains Overweight on Domino's Pizza, Lowers Price Target to $496

UPDATE: Canaan Boosts December Mining to 62 BTC, Projects FY25 Revenue Of $900M-$1.1B

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

Mesa Air Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) ("Mesa" or the "Company") today announced that it received a notice ("Notice") on January 15, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") because the Company failed to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the "Form 10-K") with the Securities and Exchange Commission. The filing delay is not the result of a forthcoming restatement of the Company's financial statements or any disagreement with the Company's auditors.

MESA

Mesa Air Group Receives Non Compliance Notice From Nasdaq

Morgan Stanley analyst John Glass maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Equal-Weight and lowers the price target from $53 to $45.

JACK

Morgan Stanley Maintains Equal-Weight on Jack In The Box, Lowers Price Target to $45

Existing mining operations, constituting the first 400 MW Phase I development at the Corsicana Facility and Riot's Rockdale and Kentucky Facilities – as well as associated expansion plans at these locations – remain in place.
As a result of this action, Riot is reducing its previously announced total self-mining hash rate capacity growth and associated capital expenditures for 2025 and will provide additional updates as this review process progresses further.
&nbsp;

RIOT

Riot Platforms Halts Previously Announced Phase II Bitcoin Mining Expansion At Corsicana Facility; Now Projects Capital Expenditures At The Facility In 2025 To Be Reduced By $245M

Posters include real-world dosing of Tyvaso DPI&#xAE; in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and data from the BREEZE open-label extension study of Tyvaso DPI detailing its long-term outcomes and dosing in patients with pulmonary arterial hypertension&nbsp;
United Therapeutics is sponsoring the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speaking events associated with the congress.
United Therapeutics is also proud to sponsor the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for Early Career PH Professionals.

UTHR

United Therapeutics To Present Clinical Data Across Its Commercial And Development Portfolio At The Pulmonary Vascular Research Institute 2025 Annual Congress

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Jason Gursky upgraded the rating for Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Neutral to Buy and maintained the price target of $587. Northrop Grumman shares closed at $482.38 on Friday. <a href="https://www.benzinga.com/quote/noc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer upgraded FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Equal-Weight to Overweight and maintained the price target of $65. FMC shares closed at $53.43 on Friday. <a href="https://www.benzinga.com/quote/fmc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Durgesh Chopra upgraded the rating for NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) from In-Line to Outperform and raised the price target from $74 to $126. NRG Energy shares closed at $104.51 on Friday. <a href="https://www.benzinga.com/quote/nrg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Simeon Gutman upgraded Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Equal-Weight to Overweight and raised the price target from $430 to $500. Ulta Beauty shares closed at $405.01 on Friday. <a href="https://www.benzinga.com/quote/ulta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Surinder Thind upgraded the rating for Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) from Hold to Buy and raised the price target from $44 to $55. Genpact shares closed at $45.11 on Friday. <a href="https://www.benzinga.com/quote/G/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ULTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072017/image-134-1024x572.png" alt="" class="wp-image-742314" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072017/image-134-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072017/image-134-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072017/image-134-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072017/image-134.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

ULTA

This Ulta Beauty Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Needham analyst Laura Martin reiterates Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and maintains $9 price target.

Needham Reiterates Buy on Outbrain, Maintains $9 Price Target

Wells Fargo analyst Michael Berg downgrades Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) from Equal-Weight to Underweight and lowers the price target from $16 to $13.

Downgrades

FRSH

Wells Fargo Downgrades Freshworks to Underweight, Lowers Price Target to $13

Riot Platforms Seeks Expert Consultants To Assess AI/HPC Opportunities; Plans To Accelerate Engagement With Potential AI/HPC Partners

Nuvve Holding ( ($NVVE) ) has provided an update. Nuvve Holdings Corp., a green energy technology firm specializing in vehicle-to-grid (V2G) platfo...

Nuvve Holding Announces 1-for-10 Reverse Stock Split

The latest update is out from Nuvve Holding ( ($NVVE) ). Nuvve Holding Corp., a pioneer in vehicle-to-grid technology, has informed its shareholder...

Nuvve Holding Executes Reverse Split, Aims for Compliance

Nuvve Holding ( ($NVVE) ) has issued an announcement. Nuvve Holding Corp. has acquired full ownership of Levo Mobility LLC after purchasing the 49%...

Nuvve Holding Acquires Full Ownership of Levo Mobility

Nuvve announces private placement of senior convertible notes, warrants

Nuvve GAAP EPS of -$2.47, revenue of $1.92M

Nuvve Holding ( ($NVVE) ) has shared an update. Nuvve Holding Corp., a leader in vehicle-to-grid (V2G) technology, reported a 16.3% increase in man...

Nuvve Holds Ground Despite Revenue Drop in 2024

Nuvve Holding Corp. (NVVE) Q3 2024 Earnings Call Transcript

Nuvve Holding Corp. ( ($NVVE) ) has released its Q3 earnings. Here is a breakdown of the information Nuvve Holding Corp. presented to its investors...

Nuvve Holding Corp. Reports Reduced Quarterly Loss

17:23 EST Nuvve Holding (NVVE) files to sell 3.92M shares of common stock for holders Published first on TheFly – the ultimate source for real-time...

Nuvve Holding files to sell 3.92M shares of common stock for holders

Nuvve Holdings files to sell 3.92M shares of common stock for holders

NVVEW

Press Releases

New Report Outlines 2025 Tipping Point in Energy Crisis and Readiness for V2G Tech for EVs

Nuvve Joins EVVE Project to Accelerate Bidirectional Charging in Europe

Nuvve Announces Private Placement of Senior Convertible Notes and Warrants

Nuvve to Provide Third Quarter 2024 Financial Update

Earnings

Nuvve Provides Third Quarter 2024 Financial Update

Nuvve Provides Webcast link to its Third Quarter 2024 Financial Update Conference Call

NUVVE HOLDING CORP.  ANNOUNCES DATE OF SPECIAL MEETING OF STOCKHOLDERS

/C O R R E C T I O N -- Nuvve Holding Corp./

REMINDER: Nuvve Holding Corp. Holds Special Meeting of Stockholders

Nuvve Launches New Product Line, Expanding Portfolio of Bidirectional and Unidirectional Charging Solutions

Comments

Nuvve Holding

Nuvve Holding (NVVE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga